StemCyte International (4178) Stock Overview
A biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4178 from our risk checks.
4178 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
StemCyte International, Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$18.20 |
| 52 Week High | NT$34.10 |
| 52 Week Low | NT$16.60 |
| Beta | 0 |
| 1 Month Change | -2.41% |
| 3 Month Change | -26.91% |
| 1 Year Change | -33.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4178 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 5.8% | 4.3% | -4.3% |
| 1Y | -33.3% | 53.5% | 95.6% |
Return vs Industry: 4178 underperformed the TW Biotechs industry which returned 53.5% over the past year.
Return vs Market: 4178 underperformed the TW Market which returned 95.6% over the past year.
Price Volatility
| 4178 volatility | |
|---|---|
| 4178 Average Weekly Movement | 7.6% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in TW Market | 12.1% |
| 10% least volatile stocks in TW Market | 2.6% |
Stable Share Price: 4178 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4178's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Tong-Young Lee | stemcytebio.com |
StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services.
StemCyte International, Ltd. Fundamentals Summary
| 4178 fundamental statistics | |
|---|---|
| Market cap | NT$3.93b |
| Earnings (TTM) | -NT$179.45m |
| Revenue (TTM) | NT$357.74m |
Is 4178 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4178 income statement (TTM) | |
|---|---|
| Revenue | NT$357.74m |
| Cost of Revenue | NT$241.71m |
| Gross Profit | NT$116.02m |
| Other Expenses | NT$295.48m |
| Earnings | -NT$179.45m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.83 |
| Gross Margin | 32.43% |
| Net Profit Margin | -50.16% |
| Debt/Equity Ratio | 0% |
How did 4178 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 19:09 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
StemCyte International, Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |